Anhydrous Docetaxel

Anhydrous Docetaxel, a potent chemotherapy drug, is being investigated in several clinical trials for its potential to treat various types of cancer. These trials aim to evaluate the efficacy and safety of Anhydrous Docetaxel, either alone or in combination with other treatments, for patients with advanced or metastatic cancers, including breast, gastric, esophageal, and Ewing sarcoma. The ongoing research seeks to improve treatment outcomes and quality of life for cancer patients.

Table of Contents

What is ANHYDROUS DOCETAXEL?

ANHYDROUS DOCETAXEL is a powerful medication used in cancer treatment. It belongs to a class of drugs known as antineoplastics, which are substances that help prevent or inhibit the growth of cancer cells[1]. The term “anhydrous” means that the medication does not contain water, which can affect its stability and effectiveness.

ANHYDROUS DOCETAXEL is also known simply as DOCETAXEL. Both names refer to the same active substance, with ANHYDROUS DOCETAXEL being a specific formulation[3]. This medication is typically administered as a solution for infusion, which means it is given directly into the bloodstream through a vein (intravenously)[1][2][3].

What Conditions Does ANHYDROUS DOCETAXEL Treat?

ANHYDROUS DOCETAXEL is used to treat various types of cancer. Based on the clinical trials information provided, it is being studied for use in the following conditions:

  • HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer: This is a specific type of breast cancer that has either spread to nearby tissues (locally advanced) or to other parts of the body (metastatic). HER2-positive means the cancer cells have a protein called HER2 on their surface, which promotes cancer growth. PIK3CA mutation refers to a specific genetic change in the cancer cells[1].
  • Advanced or Metastatic Stomach and Esophagus Cancer: This refers to cancers of the stomach or the tube connecting the throat to the stomach (esophagus) that have spread to nearby tissues or other parts of the body[2].
  • Recurrent and Primary Refractory Ewing Sarcoma: This is a rare type of cancer that occurs in bones or in the soft tissue around the bones. “Recurrent” means the cancer has come back after treatment, while “primary refractory” means the cancer did not respond to initial treatment[3].

How is ANHYDROUS DOCETAXEL Used?

ANHYDROUS DOCETAXEL is typically administered as an intravenous infusion, which means it is given directly into a vein. The dosage and frequency of treatment can vary depending on the specific condition being treated and the individual patient’s needs. Here are some examples from the clinical trials:

  • For breast cancer treatment, it may be given at a dose of 50 mg per square meter of body surface area (mg/m2) every 3 weeks[1].
  • In the treatment of stomach and esophagus cancer, it might be used at a dose of 50 mg/m2 as part of a combination therapy regimen[2].
  • For Ewing Sarcoma, the dosage being studied is 80 mg/m2, with treatments potentially lasting up to 18 weeks[3].

It’s important to note that these dosages are from clinical trials and may not reflect the final approved dosages. Always follow your doctor’s instructions regarding dosage and administration.

Current Clinical Trials

ANHYDROUS DOCETAXEL is currently being studied in several clinical trials:

  • Breast Cancer Study: This trial is comparing the effectiveness of a combination therapy including ANHYDROUS DOCETAXEL with other treatments for HER2-positive, PIK3CA mutated advanced breast cancer[1].
  • Stomach and Esophagus Cancer Study: This trial is evaluating ANHYDROUS DOCETAXEL as part of a combination therapy (called TFOX) for advanced or metastatic stomach and esophagus cancer[2].
  • Ewing Sarcoma Study: This trial is comparing different chemotherapy regimens, including one with ANHYDROUS DOCETAXEL, for the treatment of recurrent and primary refractory Ewing Sarcoma[3].

Potential Side Effects and Precautions

While the clinical trial information doesn’t provide a comprehensive list of side effects, it’s important to be aware that as a powerful cancer medication, ANHYDROUS DOCETAXEL can cause significant side effects. Some potential side effects and precautions mentioned in the trial information include:

  • Blood Cell Count Changes: The medication may affect your blood cell counts. Your doctor will monitor these closely[3].
  • Liver Function: Your liver function may be affected and will be monitored during treatment[1].
  • Heart Function: Your heart function may be monitored before and during treatment[1].
  • Fertility and Pregnancy: This medication may affect fertility. If you’re of childbearing age, you’ll need to use effective contraception during treatment and for some time afterwards. It should not be used during pregnancy or while breastfeeding[1][3].

Always discuss potential side effects and precautions with your healthcare provider before starting treatment with ANHYDROUS DOCETAXEL.

Trial Name Cancer Type Treatment Regimen Primary Endpoint
GASTFOX Advanced or metastatic oesophago-gastric adenocarcinoma FOLFOX with or without Docetaxel (TFOX) Progression-free survival at 12 months
TRINITY HER2-positive gastric or gastroesophageal cancer Trastuzumab deruxtecan plus fluoropyrimidine vs. standard chemotherapy Clearance of ctDNA at 1 year
rEECur Recurrent and Primary Refractory Ewing Sarcoma Various regimens including Docetaxel Event-free survival time
KEYNOTE-B96 Platinum-resistant recurrent ovarian cancer Pembrolizumab/placebo plus paclitaxel with or without bevacizumab Progression-free survival
Inavolisib and Phesgo Study HER2-positive, PIK3CA-mutated advanced breast cancer Inavolisib plus Phesgo vs. placebo plus Phesgo Investigator-assessed progression-free survival

Ongoing Clinical Trials on Anhydrous Docetaxel

  • Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

    Recruiting

    3 1 1
    Belgium Finland France Germany Italy Poland +1
  • Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

    Recruiting

    4 1 1 1
    Austria Belgium Czechia Denmark Finland France +4
  • Study on the Effectiveness of Abiraterone, Capivasertib, and Enzalutamide in Patients with Metastatic Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Belgium Norway Sweden
  • Study on Trastuzumab Deruxtecan and Fluorouracil for Patients with HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease

    Recruiting

    2 1 1 1
    Investigated diseases:
    Italy
  • Study of roginolisib, dostarlimab and docetaxel combination for patients with advanced non-small cell lung cancer who did not respond to previous immunotherapy and chemotherapy

    Not recruiting

    1 1 1 1
    Belgium Italy Spain
  • Study Comparing MK-2870 with Chemotherapy (Docetaxel or Pemetrexed) for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Czechia France Germany Greece Italy Poland +1
  • Study on Durvalumab and Platinum-Based Drug Combination for Patients with Stage IIB-IIIB Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Austria Czechia France Germany Hungary Italy +3
  • Study on FOLFOX and Docetaxel for Patients with Advanced or Metastatic Stomach and Esophagus Cancer

    Not recruiting

    4 1 1 1
    Investigated diseases:
    France
  • Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Belgium France Germany Hungary Italy Poland +2
  • Study of Chemotherapy With Pembrolizumab and Olaparib for Patients With Advanced Epithelial Ovarian Cancer Without BRCA Mutation

    Not recruiting

    3 1 1
    Investigated diseases:
    Belgium Czechia France Germany Hungary Italy +2

Glossary

  • Anhydrous Docetaxel: A chemotherapy drug used to treat various types of cancer by stopping cancer cells from dividing and growing.
  • HER2-positive: A type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment or procedure.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Quality of life (QoL): A measure of an individual's well-being and ability to carry out daily activities while dealing with illness and treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-inavolisib-and-phesgo-for-patients-with-her2-positive-pik3ca-mutated-advanced-breast-cancer/
  2. http://clinicaltrials.eu/trial/study-on-folfox-and-docetaxel-for-patients-with-advanced-or-metastatic-stomach-and-esophagus-cancer/
  3. http://clinicaltrials.eu/?post_type=trial&p=90962